Hyperadrenergic Postural Tachycardia Syndrome: Clinical Biomarkers and Response to Guanfacine.
L E OkamotoV UrechieStefano RigoJ J AbnerM GieseckeJames A S MuldowneyRaffaello FurlanC A ShibaoJ K Shirey-RiceJ M PulleyAndre DiedrichItalo BiaggioniPublished in: Hypertension (Dallas, Tex. : 1979) (2024)
These results are consistent with the concept that POTS is caused by a central sympathetic activation in a subset of patients, which can be identified clinically by an exaggerated DBP increase during phase 2 of the Valsalva maneuver and improved by central sympatholytic therapy. These results support further clinical trials to determine the safety and efficacy of guanfacine in patients with POTS enriched for the presence of this clinical biomarker.